Clinical Trials Browser

Has results × Breast Neoplasms, Male × Lapatinib × Clear all

NCT00770809 2025-08-15

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Phase 3 Completed

305 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Phase 2 Completed

122 enrolled 22 charts

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

NCT00820872 2019-10-21

Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer

Phase 2 Completed

30 enrolled 6 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00118157 2017-12-04

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

Phase 2 Completed

19 enrolled 6 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01868503 2017-06-26

Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer

Phase 2 Terminated

7 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00482391 2017-05-12

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Phase 2 Completed

95 enrolled 7 charts

Breast Neoplasms, Breast Neoplasms, Male